Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vγ2Vδ2 T cells in macaques

被引:68
作者
Ali, Zahida [1 ]
Shao, Lingyan [1 ,2 ]
Halliday, Lisa [3 ]
Reichenberg, Armin [4 ]
Hintz, Martin [4 ]
Jomaa, Hassan [4 ]
Chen, Zheng W. [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Ctr Primate Biomed Res, Chicago, IL 60612 USA
[2] Fudan Univ, Dept Infect Dis, Huashan Hosp, Shanghai 200433, Peoples R China
[3] Univ Illinois, Biol Resources Lab, Chicago, IL 60612 USA
[4] Univ Giessen, Inst Klin Chem & Pathobiochem, Giessen, Germany
关键词
D O I
10.4049/jimmunol.179.12.8287
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although phosphoantigen-specific V gamma 2V delta 2 T cells appear to play a role in antimicrobial and anticancer immunity, mucosal immune responses and effector functions of these gamma delta T cells during infection or phospholigand treatment remain poorly characterized. In this study, we demonstrate that the microbial phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) plus IL-2 treatment of macaques induced a prolonged major expansion of circulating V gamma 2V delta 2 T cells that expressed CD8 and produced cytotoxic perforin during their peak expansion. Interestingly, HMBPP-activated V gamma 2V delta 2 T cells underwent an extraordinary pulmonary accumulation, which lasted for 3-4 mo, although circulating V gamma 2V delta 2 T cells had returned to baseline levels weeks prior. The V gamma 2V delta 2 T cells that accumulated in the lung following HMBPP/IL-2 cotreatment displayed an effector memory phenotype, as follows: CCR5(+)CCR7(-)CD45RA(-)CD27(+) and were able to re-recognize phosphoantigen and produce copious amounts of IFN-gamma up to 15 wk after treatment. Furthermore, the capacity of massively expanded V gamma 2V delta 2 T cells to produce cytokines in vivo coincided with an increase in numbers of CD4(+) and CD8(+) alpha beta T cells after HMBPP/IL-2 cotreatment as well as substantial perforin expression by CD3(+)V gamma 2(-) T cells. Thus, the prolonged HMBPP-driven antimicrobial and cytotoxic responses of pulmonary and systemic V gamma 2V delta 2 T cells may confer immunotherapeutics against infectious diseases and cancers.
引用
收藏
页码:8287 / 8296
页数:10
相关论文
共 34 条
[1]   Cutting edge:: Human γδ T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis [J].
Altincicek, B ;
Moll, J ;
Campos, N ;
Foerster, G ;
Beck, E ;
Hoeffler, JF ;
Grosdemange-Billiard, C ;
Rodríguez-Concepción, M ;
Rohmer, M ;
Boronat, A ;
Eberl, M ;
Jomaa, H .
JOURNAL OF IMMUNOLOGY, 2001, 166 (06) :3655-3658
[2]   Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites [J].
Bonneville, M ;
Fournié, JJ .
MICROBES AND INFECTION, 2005, 7 (03) :503-509
[3]  
BUKOWSKI JF, 1995, J IMMUNOL, V154, P998
[4]   Drug-induced expansion and differentiation of Vγ9Vδ2 T cells in vivo:: The role of exogenous IL-2 [J].
Casetti, R ;
Perretta, G ;
Taglioni, A ;
Mattei, M ;
Colizzi, V ;
Dieli, F ;
D'Offizi, G ;
Malkovsky, M ;
Poccia, F .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1593-1598
[5]   A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct γδ and αβ T cell responses in primates [J].
Cendron, Delphine ;
Ingoure, Sophie ;
Martino, Angelo ;
Casetti, Rita ;
Horand, Francoise ;
Romagne, Francois ;
Sicard, Heleme ;
Fournie, Jean-Jacques ;
Poccia, Fabrizio .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (02) :549-565
[6]   Vγ2Vδ2+ T cells and anti-microbial immune responses [J].
Chen, ZW ;
Letvin, NL .
MICROBES AND INFECTION, 2003, 5 (06) :491-498
[7]   Adaptive immune response of Vγ2Vδ2 T cells:: a new paradigm [J].
Chen, ZW ;
Letvin, NL .
TRENDS IN IMMUNOLOGY, 2003, 24 (04) :213-219
[8]   Vγ9Vδ2 T cell response to colon carcinoma cells [J].
Corvaisier, M ;
Moreau-Aubry, A ;
Diez, E ;
Bennouna, J ;
Mosnier, JF ;
Scotet, E ;
Bonneville, M ;
Jotereau, F .
JOURNAL OF IMMUNOLOGY, 2005, 175 (08) :5481-5488
[9]  
Dieli F, 2000, EUR J IMMUNOL, V30, P1512, DOI 10.1002/(SICI)1521-4141(200005)30:5<1512::AID-IMMU1512>3.0.CO
[10]  
2-3